- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06270212
Medical Device for Airway Patency During Sedation (STAIRWAY-2)
Complementary Systematic Evaluation of a New Medical Device (STAIRWAY) for Open Airways During Sedation
OVERALL SYNOPSIS
PART A: Systematic evaluation in spontaneously breathing healthy volunteer study participants
- of cumulative duration of manual measures for airway patency and for mask ventilation with airway device prototype (STAIRWAY) vs. standard procedure (no device) during target-controlled induction of mild and moderate-to-deep sedation with propofol in the supine position
- of minimum anteroposterior and lateral transpharyngeal distances at tongue-base and soft-palate levels, determined by magnetic resonance imaging (MRI) with STAIRWAY vs. biteblock or no device during no, mild and moderate-to-deep steady-state sedation with propofol in the supine position.
PART B: Systematic evaluation (in the body position [normally supine] considered most optimal for the procedural intervention) of the cumulative duration
- of adjuvant manual airway support and ventilation
- of respiratory arrest (interrupted monitoring of endtidal carbon dioxide [ETCO2])
- of hypoxemia (hemoglobin saturation of oxygen [SpO2] <95 %), and
- of perceived sedational comfort, of sedational and procedural usability, and of sedational and procedural preference with STAIRWAY vs. standard procedure (biteblock or no device) during PS according to SOC for scheduled diagnostic or therapeutic procedures planned to be carried out under PS with propofol in spontaneously breathing study patients.
Study Overview
Status
Intervention / Treatment
Detailed Description
NUMBERS OF STUDY PARTICIPANTS
PART A: 12 (6 female) evaluable study participants (adult healthy volunteers).
PART B: 34 evaluable study participants (adult patients).
DURATION OF INVESTIGATION FOR COLLECTION OF STUDY DATA
PART A: Two months (February until March 2024).
PART B: Six months (February until July 2024).
STUDY FOLLOW-UP
PART A: Short-term questionnaire-based follow-up by individual study participants' survey at study site immediately after appropriate awakening from, and completed collection of study data during, mild and moderate-to-deep steady-state sedation.
PART B: Short-term questionnaire-based follow-up by individual study patients', sedationists' and procedural interventionists' surveys at the study site immediately after appropriate awakening from, and completed collection of study data during, PS according to SOC.
PRIMARY STUDY OBJECTIVES
PART A: Randomized paired crossover comparison of MRI-derived minimum anteroposterior and lateral transpharyngeal distances at tongue-base and soft-palate levels during spontaneous breathing of pure oxygen at mild (Observer Assessment of Alertness/Sedation [OAA/S] level 4) and moderate-to-deep (OAA/S level 2-3) sedation - assessed by estimated target organ levels of propofol according to computerized infusion pump settings, and by bedside judgements of OAA/S levels - in the supine body position with STAIRWAY vs. standard procedure (biteblock or no device).
PART B: Randomized unpaired comparison (by continuous systematic observation and recording) of cumulative duration of adjuvant use of manual airway support and ventilation with STAIRWAY vs. standard procedure (no device) during PS according to SOC - assessed by estimated target tissue levels of propofol according to computerized infusion pump settings, by clinical bedside judgements of sedation levels according to OAA/S, and by monitored Bispectral Index Score (BIS) levels - for scheduled diagnostic or therapeutic procedures planned to be carried out under PS with propofol in the body position (normally supine) most optimal for the procedure.
SECONDARY STUDY OBJECTIVES
PART A: Randomized unpaired comparison of cumulative duration of interrupted ETCO2 monitoring, of SpO2 <95 %, and of adjuvant manual airway measures and mask ventilation, with STAIRWAY vs. no device during computerized target-controlled intravenous (iv) infusion (TCI) of propofol to attain mild and moderate-to-deep steady-state levels of sedation. Individual questionnaire-based evaluation of perceived sedational comfort (VAS units).
PART B: Randomized unpaired comparison of incidence and cumulative duration of interrupted ETCO2 monitoring, and of SpO2 <95 %, during PS according to SOC - assessed by algorithm-based estimated target organ levels of propofol, and by clinical bedside judgements of sedation levels according to OAA/S - for scheduled diagnostic or therapeutic procedures planned to be carried out under PS with propofol in the body position (normally supine) most optimal for the procedure with STAIRWAY vs. no device (standard procedure). Individual questionnaire-based evaluation of perceived sedational comfort (VAS units) by unblinded study patients, of perceived sedational usability (VAS units) by unblinded sedationists, and of perceived procedural conditions (VAS units) by blinded interventionists, soon after completion of PS according to SOC with STAIRWAY or no device.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jonas Åkeson, Professor
- Phone Number: +46 0708311113
- Email: jonas.akeson@med.lu.se
Study Contact Backup
- Name: Magnus Ljungvall, Consultant
- Phone Number: +46 0705445502
- Email: magnus.ljungvall@med.lu.se
Study Locations
-
-
Skåne
-
Malmö, Skåne, Sweden, 20502
- Recruiting
- Skåne University Hospital
-
Contact:
- Magnus Ljungvall, MD
- Phone Number: +46-705445502
- Email: magnus.ljungvall@med.lu.se
-
Contact:
- Jonas Åkeson, PhD, Professor
- Phone Number: +46-708311113
- Email: jonas.akeson@med.lu.se
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
INCLUSION CRITERIA:
PART A: Adult (18-65 years). No known allergy or hypersensitivity to drugs used for routine sedation or to materials (PP or EVA) comprising STAIRWAY. Medically healthy with no comorbidity according to careful investigation by senior anaesthesiologist in charge of the sedation. No in situ magnetic device or implant. No cognitive or psychosocial distress, particularly including claustrofobia. Complete dentation. No mobile teeth, mobile reconstructions or orthodontic braces. Non-pregnant. No ongoing breast-feeding. Ability to communicate in Swedish. Oral and written informed consent to inclusion as healthy volunteer study participant.
PART B: Adult (18 years and above) scheduled for elective diagnostic or therapeutic procedures under PS with propofol. No known allergy or hypersensitivity to drugs used for PS or to materials (PP or EVA) comprising STAIRWAY. Medical comorbidity corresponding to ASA class I-III. No cognitive or psychosocial distress. Complete or partial dentation. No mobile teeth, mobile reconstructions or orthodontic braces. Ability to communicate in Swedish. Oral and written informed consent to inclusion as study participant.
EXCLUSION CRITERIA:
PARTS A-B: Withdrawal of informed consent. Suspected or manifest unforeseen severe allergic reaction. Inability to obtain enough useful study data for practical or medicotechnical reasons.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: STAIRWAY
Unpaired evaluation of STAIRWAY during induction of steady-state sedation in volunteer study participants (PART A), and during induction and maintenance of PS according to SOC in study patients (PART B).
|
Evaluation of STAIRWAY (new airway device) during sedation.
|
Other: NO DEVICE
Unpaired evaluation of NO DEVICE during induction of steady-state sedation in volunteer study participants (PART A), and during induction and maintenance of PS according to SOC in study patients (PART B).
|
Evaluation of NO DEVICE during sedation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Transpharyngeal distance during moderate-to-deep steady-state sedation.
Time Frame: Five months
|
Differences in minimum anteroposterior and lateral transpharyngeal distances (mm) at tongue-base and soft-palate levels, determined by an experienced radiologist with specific MRI competence, based on MRI scans obtained with a General Electric SIGNA™ Architect 3T MRI scanner, between use of STAIRWAY vs. NO DEVICE during moderate-to-deep (OAA/S level 2-3) steady-state sedation with propofol [PART A].
|
Five months
|
Duration of manual airway support during PS for clinical procedures.
Time Frame: Six months
|
Difference in cumulative duration (s) of adjuvant manual measures for airway support between use of STAIRWAY vs. NO DEVICE during procedural sedation with propofol according to standard of care for scheduled diagnostic or therapeutic procedures planned to be carried out under procedural sedation with propofol [PART B].
|
Six months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Transpharyngeal distance during mild steady-state sedation.
Time Frame: Five months
|
Differences in minimum anteroposterior and lateral transpharyngeal distances (mm) at tongue-base and soft-palate levels, determined by an experienced radiologist with specific MRI competence, based on MRI scans obtained with a General Electric SIGNA™ Architect 3T MRI scanner, at tongue-base and soft-palate levels, between use of STAIRWAY vs. NO DEVICE during mild (OAA/S level 4) steady-state sedation with propofol [PART A].
|
Five months
|
Duration of interrupted capnometric monitoring during sedation.
Time Frame: Six months
|
Differences in cumulative duration (s) of interrupted ETCO2 monitoring between STAIRWAY vs. NO DEVICE during induction of mild and moderate-to-deep levels of sedation (Philips Expression MR400 monitor) with propofol [PART A], and during induction and maintenance of procedural sedation with propofol according to standard of care (Philips MX800 monitor) for scheduled diagnostic or therapeutic procedures planned to be carried out under procedural sedation with propofol [PART B].
|
Six months
|
Duration of manual airway support during induction of steady-state sedation.
Time Frame: Five months
|
Differences in cumulative duration (s) of manual measures for adjuvant airway support between STAIRWAY vs. NO DEVICE during induction of mild and moderate-to-deep steady-state sedation with propofol [PART A].
|
Five months
|
Sedational comfort
Time Frame: Six months
|
Perceived sedational comfort, individually assessed by study participants between 0.0 (minimum score) and 10.0 (maximum score) on a 100 mm visual analogue score line, with STAIRWAY or NO DEVICE, after induction of mild and moderate-to-deep steady-state sedation with propofol [PART A], and after procedural sedation with propofol according to standard of care for scheduled diagnostic or therapeutic procedures planned to be carried out under procedural sedation with propofol [PART B].
|
Six months
|
Conditions for sedation
Time Frame: Six months
|
Perceived conditions for sedation, individually assessed by sedationists between 0.0 (minimum score) and 10.0 (maximum score) on a 100 mm visual analogue score line, and individual preference, with STAIRWAY or NO DEVICE, after procedural sedation with propofol according to standard of care for scheduled diagnostic or therapeutic procedures planned to be carried out under procedural sedation with propofol [PART B].
|
Six months
|
Conditions for procedural intervention
Time Frame: Six months
|
Perceived conditions for procedural intervention, individually assessed by interventionists/surgeons between 0.0 (minimum score) and 10.0 (maximum score) on a 100 mm visual analogue score line, and individual preference, with STAIRWAY or NO DEVICE, after procedural sedation with propofol according to standard of care for scheduled diagnostic or therapeutic procedures planned to be carried out under procedural sedation with propofol [PART B].
|
Six months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jonas Åkeson, Professor, Lund University, Malmö, Sweden
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIV-ID 23-08-043797
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Airway Obstruction
-
Beth Israel Deaconess Medical CenterMedWaves, IncRecruitingAirway Obstruction | Central Airway ObstructionUnited States
-
McMurray Medical Group, LLCCompletedUpper Airway ObstructionUnited States
-
Massachusetts General HospitalCompletedUpper Airway ObstructionUnited States
-
Rigshospitalet, DenmarkCompletedUpper Airway ObstructionDenmark
-
Zhongda HospitalUnknownMalignant Airway ObstructionChina
-
Assistance Publique - Hôpitaux de ParisRecruitingRespiratory Distress | Upper Airway ObstructionFrance
-
ResMedCompletedRespiratory Failure | Respiratory Insufficiency | Upper Airway ObstructionUnited States
-
Massachusetts General HospitalCompletedMechanical Ventilation Complication | Upper Airway ObstructionUnited States
-
Aerin MedicalOhio State UniversityCompletedNasal ObstructionUnited States
-
University of RochesterCompletedUpper Airway ObstructionUnited States